Because of the very short half-life of factor VII, prophylaxis in factor VII deficiency is considered a difficult endeavor. The clinical efficacy and safety of prophylactic regimens, and indications for their use, were evaluated in factor VII-deficient patients in the Seven Treatment Evaluation Registry. Prophylaxis data (38 courses) were analyzed from 34 patients with severe factor VII deficie...

in this study, anion-exchange chromatography was used to purify factor vii and factor ix from prothrombin complex (ppsb), which contains coagulation factors ii, vii, ix and x. for this purpose, deae-sepharose cl-6b gel , pharmacia column xk-26 , high flow rate and two stepwise gradients with phosphate citrate buffer were used. the yield of the two lyophylized products, factor vii and factor ix ...

Recombinant activated factor VII is commonly used for the treatment of hemophiliac patients with inhibitors and has been studied for use in trauma. We report the use of recombinant activated factor VII for a male patient who was injured in a motor vehicle accident. We also summarize the animal studies and clinical trials that have been reported.

Dietary studies have established a connection between plasma lipoproteins and coagulation factor VII. The present study was undertaken to specifically examine whether factor VII is activated during alimentary lipemia and to investigate the relations of factor VII mass and activity state with fasting and postprandial lipoproteins and free fatty acids (FFAs). Factor VII levels were therefore dete...

Ischemic heart disease is caused by a combination of and interaction between a number of genetic and environmental factors. In a study of a group of healthy men from the United Kingdom, such an interaction was identified between the levels of plasma triglycerides and genetic variation determining plasma levels of factor VII, a clotting factor that is associated with risk of ischemic heart disea...

Clotting Factor VII activity emerges as a highly significant predictive factor for development of cardiovascular disease (CVD) In prospective trials. We have previously shown that In hypertriglyceridemlc Individuals a fraction of their clotting Factor VII molecules is present in an activated state In phosphollpase C-sensitive complexes in plasma. These complexes may explain the increased Factor...

Clotting Factor VII activity emerges as a highly significant predictive factor for development of cardiovascular disease (CVD) in prospective trials. We have previously shown that in hypertriglyceridemic individuals a fraction of their clotting Factor VII molecules is present in an activated state in phospholipase C-sensitive complexes in plasma. These complexes may explain the increased Factor...